CAR T-Cell Therapy

Welcome to the CAR T-Cell Therapy Resource Center! Take a look around and find current information, news, literature, and other resources from this area of oncology treatment. We hope this site is helpful to your practice. If you have any feedback or questions, please contact editor@advancedpractitioner.com

Kathryn Ciccolini, AGACNP-BC, DNP, MSN, OCN
CAR-T/BMT Clinical Program Manager
Bone Marrow and Stem Cell Transplantation Program
Mount Sinai Hospital

CAR T-Cell Therapy Resource Center

Interview With Meaghan Ryan, MSN, FNP-BC: One Center's Process for Administering Immune Effector Cells

The EBMT/EHA CAR-T Cell Handbook

Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

CAR T-Cell Therapy for Large B-Cell Lymphoma

ASTCT 2022 National Fludarabine Shortage for HCT and CAR T-Cell Recipients: Frequently Asked Questions

NCCN: Immunotherapy Side Effects - CAR T-Cell Therapy

BMS Press Release

Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

JAMA

“Off-the-Shelf” CAR T-Cell Therapy Tested in Pediatric B-Cell Leukemia

Blood (2022 ASH Abstract)

Observational Cohort Study of People Living with HIV (PWH) Treated with CD19-Directed CAR T Cell Therapy for B-Cell Lymphoid Malignancies—Interim Results of AIDS Malignancy Consortium (AMC) Study AMC-113.

Blood (2022 ASH Abstract)

Targeting CNS Lymphoma with Intravenous Axicabtagene Ciloleucel: Evidence for Transcriptional Evolution Towards a Prominent Interferon Signature in CAR-T Cells Trafficking to the Tumor Site.

Blood (2022 ASH Abstract)

Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy

Blood

Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy

Lancet Haematology

Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study

Journal of Clinical Oncology

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.

Blood

Interventions and outcomes of multiple myeloma patients receiving salvage treatment after BCMA-directed CAR T therapy

Lancet Haematology

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

Identifying CRS in Patients Who Underwent CAR T-Cell Infusion

Cytopenias After CAR T-cell Therapy: Varying Predictive Markers, Duration

Cardiovascular Events Following CAR T-Cell Therapy Are Common, Especially in Conjunction With CRS

Fast Facts #12: BCMA Targets